AZ Oncology

Discussion in 'AstraZeneca' started by anonymous, Mar 24, 2024 at 7:21 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    What are your thoughts about working in this division? Is there a future? Good pay etc.
     

  2. anonymous

    anonymous Guest

    It is the future of AZ.
     
  3. anonymous

    anonymous Guest

    been that way since Pascal took over—-in 2014. OP is fishing for something.
     
  4. anonymous

    anonymous Guest

    Oncology is a good place with a pipeline. Pascal is out of touch and needs to retire. Isn't this a stock holders company! Why isn't he removed for this EV thing? It will kill productivity.
     
  5. anonymous

    anonymous Guest

    He has not been removed because the board does not care about the incessant bitching of idiotic reps. You provide little value outside of being a mobile product advertisement.
     
  6. anonymous

    anonymous Guest

    So you think we shouldn't work just drive around and wave to people?
     
  7. anonymous

    anonymous Guest

    Just wait until turnover and decreased productivity start hitting sales. At that point, maybe the board will finally acknowledge his best days are well bebind him and how out of touch he has become.

    I mean the EV's for all is bad enough but the carbon footprint linitations on employees travel defies all logic and common sense. Talk about idiotic.

    He needs to be gone yesterday with this garbage that no one with a brain and that is being honest understands or agrees with. Idiotic would describe AZ's virtue signaling carbon footprint initiative to a tee.
     
  8. anonymous

    anonymous Guest


    You’re getting what he is incentivized by the BOD and BlackRock to give you. And be careful what you wish for. Nobody leans harder into ESG and DEI than Dave.
     
  9. anonymous

    anonymous Guest

    That means my long black rock will be appreciated
     
  10. anonymous

    anonymous Guest

    Merck then made its biggest splash with a $4 billion upfront tie-up with Daiichi Sankyo, one of the leaders in ADCs with its Enhertu franchise. The first of three ADCs from that co-development and co-commercialization agreement is due for an FDA approval decision by June 26 as the partners look to bring the HER3-targeted patritumab deruxtecan to market.

    What indication is this for?
     
  11. anonymous

    anonymous Guest

    decreased productivity? You mean you’d do less work than you already do? Is that even possible? Get lost lunchboy
     
  12. anonymous

    anonymous Guest

    There will be no unusual turnover or dip in sales. If you quit, which I doubt you will, they have hundreds of resumes on file to fill your position. You are a number. Nothing more. Be glad you have this job where you work only a few hours a week and management tolerates it. Try getting a “real job” with only your catering skills! You will stay unemployed for years!
     
  13. anonymous

    anonymous Guest

    You are correct about everyone being a number. Don’t for a second ever think you’ve built up relationships that will protect you, or that you’ve achieved enough success to make it through a downsizing. You haven’t. And it only takes one person who wants you gone to make it so, especially if those you reported to are too cowardly to defend you.